Verve Therapeutics (VERV) Environmental, Social & Governance (ESG) Data

Employees

Data from SEC filings

Employee count

ESG framework mentions

In last year of SEC filings

Sustainability Accounting Standards Board (SASB)

No mentions

Global Reporting Initiative (GRI)

No mentions

Task Force on Climate-related Financial Disclosures (TCFD)

No mentions

UN Sustainable Development Goals (SDGs)

No mentions

ESG term mentions

In last year of SEC filings

Agriculture Biodegradable Climate Environment Environmental Escape Intensity Materials Nature Offset Package Packaging Pandemic Raw Materials Recycled Recycling Regeneration Regenerative Toxic Waste Wind Access Affordability African American Asian Benefits Black California Consumer Privacy Act Citizenship Collective Bargaining Community Culture Customer Cyber Cybersecurity Data Privacy Data Security Death Demographic Disability Diversity Drug Pricing Employee Employee Engagement Engagement Ethnicity Gender General Data Protection Regulation Health and Safety Health Care Healthcare Hire Hiring Hispanic Human Capital Human Resources Incident Injuries Injury Latinx LGBTQ Privacy Product Quality Product Safety Recall Recruit Recruitment Reimbursement Retention Retirement Safety Satisfaction Skills Social Society Supplier Supply Chain Talent Training Union Volunteer Women Workers Workforce Anti-corruption Assessment Assurance Attorneys General Audit Bonus Bribery Chronic Classified Classified Board Commitment Conflict of Interest Corporate Governance Corruption Department of Ethics Executive Compensation Expert Fraud Goals Governance Hedging Incentive Incentivize Independence Independent Innovation Innovative Investigation Lawsuit Leadership Litigation Long-term Majority Mission Oversee Oversight Plaintiff Poison Pill Purpose Quality Standard R&D Recoup Reputation Reputational Research and Development Responsibility Responsible Self-evaluation Special Meeting Strategy Sustainable Targets Tax Transparency Transparent Voting Rights

Shareholder alignment

Proxy contests and exempt solicitations in last 3 years

No recent proxy contest or exempt solicitation filings from shareholders.

Vote support at last AGM

The Company held its Annual Meeting of Stockholders on June 9, 2022 (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders considered and voted on the two proposals set forth below, each of which is described in greater detail in the Company’s definitive proxy statement, filed with the SEC on April 29, 2022. The final voting results are set forth below.
Proposal 1 – Election of Class I Directors
The stockholders of the Company elected John Evans and Krishna Yeshwant, M.D. to serve as Class I directors of the Company, for a three-year term ending at the annual meeting of stockholders to be held in 2025 and until each of their successors has been duly elected and qualified or until their earlier resignation or removal. The results of the stockholders’ vote with respect to the election of the Class I directors were as follows:

	Votes For	Votes Withheld	Broker Non-Votes

John Evans	30,009,983	9,111,871	8,241,140
Krishna Yeshwant, M.D.	34,087,840	5,034,015	8,241,140

Proposal 2 – Ratification of Appointment of the Company’s Independent Registered Public Accounting Firm
The stockholders of the Company ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022. The results of the stockholders’ vote with respect to such ratification were as follows:


Votes For	Votes Against	Votes Abstaining
42,665,206	4,205,067	492,722

No other matters were submitted to or voted on by the Company’s stockholders at the Annual Meeting.